[In vitro testing and clinical experience with 5-fluorouracil in gynaecologic cancer (author's transl)].
201 pretherapeutic tests for sensitivity of gynaecologic cancers against 5-fluorouracil were performed. Only 8.5% of cases proved to be sensitive in tissue culture. Clinical results with 5-FU monotherapy were unsatisfactory. 5-FU should only be used very critically in gynaecologic neoplasims. The value of predictive tests for sensitivity against cytostatics in planning individualized selective chemotherapy is emphasized.
D000328:Adult; D000368:Aged; D046508:Culture Techniques; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy; D014625:Vaginal Neoplasms / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy
D005472:Fluorouracil
Die in-vitro-Testung und klinische Erfahrungen mit 5-Fluor-Uracil bei gynäkologischen Karzinomen